Big pharma experience added to help iOnctura's move into the clinic

12 March 2019

Privately-held Swiss biotech iOnctura has completed the line-up of its executive leadership team.

The oncology-focused company has named Michael Lahn as its chief medical officer (CMO) and appointed Zoë Johnson chief scientific officer (CSO).

iOnctura is developing molecules with dual therapeutic potential in cancer and fibrotic indications. Its lead program, IOA-244, is a selective PI3Kδ inhibitor developed as a targeted therapy for solid tumors that are burdened with an immune-suppressive microenvironment and an elevated PI3Kδ signature. First-in-human studies in patients are expected to start this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK